Quarterly report · Q2
3583.TEDINET S100S6MI
Period2023-04-01 → 2023-09-30
Filed2023-11-10
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥2.6bn | 2023-04-01 → 2023-09-30 | Cons. | Net sales |
| Revenue | ¥5.3bn | 2022-04-01 → 2023-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥2.7bn | 2022-04-01 → 2022-09-30 | Cons. | Net sales |
| Operating income | ¥270m | 2023-04-01 → 2023-09-30 | Cons. | Operating income |
| Operating income | ¥341m | 2022-04-01 → 2022-09-30 | Cons. | Operating income |
| Ordinary income | ¥294m | 2023-04-01 → 2023-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥639m | 2022-04-01 → 2023-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥366m | 2022-04-01 → 2022-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥294m | 2023-04-01 → 2023-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥405m | 2022-04-01 → 2022-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥218m | 2023-04-01 → 2023-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥469m | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥270m | 2022-04-01 → 2022-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥218m | 2023-04-01 → 2023-09-30 | Cons. | Profit loss |
| Net income | ¥270m | 2022-04-01 → 2022-09-30 | Cons. | Profit loss |
| Total assets | ¥9.5bn | at 2023-09-30 | Cons. | Assets |
| Total assets | ¥9.3bn | at 2023-03-31 | Cons. | Assets |
| Total assets | ¥9.4bn | at 2022-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥3.5bn | at 2023-09-30 | Cons. | Liabilities |
| Total liabilities | ¥3.5bn | at 2023-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥6.0bn | at 2023-09-30 | Cons. | Net assets |
| Net assets / equity | ¥5.8bn | at 2023-03-31 | Cons. | Net assets |
| Net assets / equity | ¥5.6bn | at 2022-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥2.9bn | at 2023-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥2.5bn | at 2023-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥2.8bn | at 2023-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥2.4bn | at 2023-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥2.5bn | at 2022-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥2.4bn | at 2022-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥601m | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥338m | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥190m | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥99m | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥184m | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥44m | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥139m | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥206m | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥114m | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥78.21 | 2023-04-01 → 2023-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥38.64 | 2023-07-01 → 2023-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥169.17 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥97.39 | 2022-04-01 → 2022-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥39.08 | 2022-07-01 → 2022-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 63.1% | at 2023-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 62.5% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 59.8% | at 2022-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 30
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2023-04-01 → 2023-09-30 | ¥2.6bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2023-04-01 → 2023-09-30 | ¥2.6bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥645,000 |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2023-04-01 → 2023-09-30 | ¥430m |
| jpcrp040300-q2r_E00584-000Medical Productsreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥721m |
| jpcrp040300-q2r_E00584-000Medical Productsreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥720m |
| jpcrp040300-q2r_E00584-000Medical Productsreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥645,000 |
| jpcrp040300-q2r_E00584-000Medical Productsreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥48m |
| jpcrp040300-q2r_E00584-000Technological Productsreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥1.9bn |
| jpcrp040300-q2r_E00584-000Technological Productsreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥1.9bn |
| jpcrp040300-q2r_E00584-000Technological Productsreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥382m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-04-01 → 2023-09-30 | ¥2.6bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-04-01 → 2023-09-30 | ¥2.6bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥645,000 |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-04-01 → 2023-09-30 | ¥430m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2022-04-01 → 2022-09-30 | ¥2.7bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2022-04-01 → 2022-09-30 | ¥2.7bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥2m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2022-04-01 → 2022-09-30 | ¥479m |
| jpcrp040300-q2r_E00584-000Medical Productsreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥696m |
| jpcrp040300-q2r_E00584-000Medical Productsreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥693m |
| jpcrp040300-q2r_E00584-000Medical Productsreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥2m |
| jpcrp040300-q2r_E00584-000Medical Productsreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥44m |
| jpcrp040300-q2r_E00584-000Technological Productsreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥2.0bn |
| jpcrp040300-q2r_E00584-000Technological Productsreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥2.0bn |
| jpcrp040300-q2r_E00584-000Technological Productsreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥435m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-04-01 → 2022-09-30 | ¥2.7bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-04-01 → 2022-09-30 | ¥2.7bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥2m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-04-01 → 2022-09-30 | ¥479m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 520
| Item | Context | Value | Unit |
|---|---|---|---|
| Notes additional information quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes regarding promissory notes due on balance sheet date (text) | CurrentQuarterInstant | Text · Plus | |
| Major components of selling general and administrative expenses (text) | CurrentYTDDuration | Text · Plus | |
| Reconciliation of ending balance of cash and cash equivalents with account balances per balance sheet (text) | CurrentYTDDuration | Text · Plus | |
| Notes regarding dividend (text) | Prior1YTDDuration | Text · Plus | |
| Notes when there is significant changes in amounts of equity (text) | Prior1YTDDuration | Text · Plus | |
| Notes regarding dividend (text) | CurrentYTDDuration | Text · Plus | |
| Notes when there is significant changes in amounts of equity (text) | CurrentYTDDuration | Text · Plus | |
| Notes segment information etc quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Description of nature of differences between profit loss of reportable segments total and quarterly financial statements (text) | Prior1YTDDuration | Text · Plus | |
| Information about impairment loss of non current assets or goodwill etc for each reportable segment (text) | Prior1YTDDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | CurrentYTDDuration | Text · Plus | |
| Description of nature of differences between profit loss of reportable segments total and quarterly financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Information about impairment loss of non current assets or goodwill etc for each reportable segment (text) | CurrentYTDDuration | Text · Plus | |
| Disclosure of changes etc in reportable segments (text) | CurrentYTDDuration | Text · Plus | |
| Notes revenue recognition quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes per share information quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes significant events after reporting period quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Other information consolidated financial statements etc (text) | CurrentYTDDuration | Text · Plus | |
| Information about company which provides guarantee to reporting company (text) | FilingDateInstant | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |